Cutler Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $603K | Sell |
26,900
-15,800
| -37% | -$1.94M | 0.2% | 122 |
|
|
2023
Q4 | $301K | Buy |
42,700
+500
| +1% | +$48K | 0.03% | 577 |
|
|
2023
Q3 | $642K | Buy |
42,200
+34,700
| +463% | +$3.92M | 0.07% | 352 |
|
|
2023
Q2 | $208K | Sell |
7,500
-8,300
| -53% | -$1.07M | 0.03% | 595 |
|
|
2023
Q1 | $432K | Sell |
15,800
-6,900
| -30% | -$895K | 0.04% | 395 |
|
|
2022
Q4 | $722K | Sell |
22,700
-18,500
| -45% | -$2.14M | 0.06% | 340 |
|
|
2022
Q3 | $580K | Buy |
41,200
+4,700
| +13% | +$474K | 0.04% | 473 |
|
|
2022
Q2 | $116K | Sell |
36,500
-12,600
| -26% | -$927K | 0.01% | 1349 |
|
|
2022
Q1 | $234K | Sell |
49,100
-25,100
| -34% | -$1.92M | 0.01% | 1096 |
|
|
2021
Q4 | $509K | Buy |
74,200
+69,100
| +1,355% | +$5.91M | 0.02% | 734 |
|
|
2021
Q3 | $15K | Sell |
5,100
-6,200
| -55% | -$478K | ﹤0.01% | 3613 |
|
|
2021
Q2 | $20K | Buy |
11,300
+7,100
| +169% | +$538K | ﹤0.01% | 3308 |
|
|
2021
Q1 | $15K | Sell |
4,200
-17,600
| -81% | -$1.62M | ﹤0.01% | 3457 |
|
|
2020
Q4 | $582K | Buy |
21,800
+7,700
| +55% | +$1.14M | 0.03% | 575 |
|
|
2020
Q3 | $232K | Buy |
14,100
+900
| +7% | +$137K | 0.01% | 852 |
|
|
2020
Q2 | $526K | Buy |
13,200
+900
| +7% | +$122K | 0.03% | 478 |
|
|
2020
Q1 | $151K | Buy |
12,300
+100
| +0.8% | +$11.4K | 0.01% | 1114 |
|
|
2019
Q4 | $118K | Sell |
12,200
-20,800
| -63% | -$2.1M | 0.01% | 1111 |
|
|
2019
Q3 | $37K | Sell |
33,000
-1,000
| -3% | -$118K | ﹤0.01% | 1756 |
|
|
2019
Q2 | $656K | Buy |
34,000
+18,400
| +118% | +$2.24M | 0.06% | 286 |
|
|
2019
Q1 | $135K | Sell |
15,600
-10,200
| -40% | -$1.31M | 0.01% | 845 |
|
|
2018
Q4 | $388K | Sell |
25,800
-3,900
| -13% | -$488K | 0.04% | 410 |
|
|
2018
Q3 | $1.74M | Sell |
29,700
-2,300
| -7% | -$314K | 0.12% | 156 |
|
|
2018
Q2 | $1.36M | Buy |
32,000
+12,300
| +62% | +$1.16M | 0.11% | 191 |
|
|
2018
Q1 | $192K | Sell |
19,700
-27,100
| -58% | -$1.81M | 0.02% | 844 |
|
|
2017
Q4 | $742K | Sell |
46,800
-39,100
| -46% | -$2.07M | 0.03% | 407 |
|
|
2017
Q3 | $858K | Buy |
85,900
+7,100
| +9% | +$284K | 0.03% | 403 |
|
|
2017
Q2 | $360K | Sell |
78,800
-22,300
| -22% | -$726K | 0.01% | 888 |
|
|
2017
Q1 | $255K | Sell |
101,100
-115,200
| -53% | -$3.57M | 0.01% | 1027 |
|
|
2016
Q4 | $470K | Sell |
216,300
-155,100
| -42% | -$6.23M | 0.02% | 727 |
|
|
2016
Q3 | $6.12M | Sell |
371,400
-290,300
| -44% | -$8.78M | 0.27% | 56 |
|
|
2016
Q2 | $2.01M | Buy |
661,700
+514,600
| +350% | +$9.53M | 0.1% | 141 |
|
|
2016
Q1 | $574K | Sell |
147,100
-65,000
| -31% | -$1.14M | 0.04% | 462 |
|
|
2015
Q4 | $1.27M | Buy |
+212,100
| New | +$6.88M | 0.07% | 270 |
|
Other funds holding SRPT
ACA
FCM
Cutler Group's SRPT Position: Q1 2024 in Review
Cutler Group reduced its Sarepta Therapeutics (SRPT) stake by 63% in Q1 2024, selling an estimated $1.43M and leaving 6,900 shares worth $893K. The position accounts for 0.29% of the portfolio, ranked #77.
Cutler Group first reported a position in SRPT in Q4 2015 and has held it in 32 quarters since. The position peaked at $3.93M in Q3 2016. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.
- Cutler Group held 6,900 shares of Sarepta Therapeutics worth $893K as of Q1 2024.
- Cutler Group sold 11,634 Sarepta Therapeutics shares in Q1 2024, an estimated $1.43M.
- Sarepta Therapeutics made up 0.29% of Cutler Group's portfolio in Q1 2024, its #77 holding.
- Cutler Group first reported a position in Sarepta Therapeutics in Q4 2015 and has held it in 32 quarters since.
- Cutler Group's Sarepta Therapeutics position peaked at $3.93M in Q3 2016.
- 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.